Alps Advisors Inc Autolus Therapeutics PLC Transaction History
Alps Advisors Inc
- $17.2 Billion
- Q2 2025
A detailed history of Alps Advisors Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Alps Advisors Inc holds 143,614 shares of AUTL stock, worth $235,526. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,614
Previous 199,709
28.09%
Holding current value
$235,526
Previous $309,000
5.83%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AUTL
# of Institutions
100Shares Held
164MCall Options Held
0Put Options Held
39.3K-
Wellington Management Group LLP Boston, MA27.1MShares$44.5 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$33.6 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$27.8 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$27.6 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$27.3 Million98.24% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $149M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...